GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance

Molecular Metabolism

Volumn 3, Issue 9, 2014, Pages 823-833

  Taher, Jennifer ^a,b   Baker, Christopher L ^a   Cuizon, Carmelle ^a   Masoudpour, Hassan ^a   Zhang, Rianna ^a   Farr, Sarah ^a,b   Naples, Mark ^a   Bourdon, Celine ^a   Pausova, Zdenka ^a   Adeli, Khosrow ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Fasting dyslipidemia; Glucagon like peptide 1 (GLP 1); Hepatic steatosis; Incretin; Insulin resistance; Very low density lipoprotein (VLDL)

Indexed keywords

APOLIPOPROTEIN B100; CARBOHYDRATE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; LIPID; MESSENGER RNA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN THIRD VENTRICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DYSLIPIDEMIA; ENERGY METABOLISM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; LIVER LEVEL; MALE; METABOLIC REGULATION; NONHUMAN; RESPIRATORY EXCHANGE RATIO; SATIETY; SYRIAN HAMSTER; VAGOTOMY; WEIGHT REDUCTION;

CRICETINAE; MESOCRICETUS AURATUS;

EID: 84919696212     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.09.005     Document Type: Article

References (38)

1. Adeli K., Taghibiglou C., Van Iderstine S.C., Lewis G.F. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends in Cardiovascular Medicine 2001, 11(5):170-176.
2. Hein G., Baker C., Hsieh J., Farr S., Adeli K. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 2013, 62(2). pmid:PMID:%2023028139.
3. Hsieh J., Longuet C., Baker C.L., Qin B., Federico L.M., Drucker D.J., et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010, 53(3):552-561.
4. Schwartz E.A., Koska J., Mullin M.P., Syoufi I., Schwenke D.C., Reaven P.D. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010, 212(1):217-222.
5. Farr S., Taher J., Adeli K. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. Cardiovascular Hematological Disorders Drug Targets 2014, 14(2):126-136.
6. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 2008, 24(1):275-286.
7. Horton E.S., Silberman C., Davis K.L., Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010, 33(8):1759-1765.
8. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2006, 436-447. Sect. 8.
9. Mells J.E., Fu P.P., Sharma S., Olson D., Cheng L., Handy J.A., et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a western diet. American Journal of Physiology. Gastrointestinal and Liver Physiology 2012, 302(2):G225-G235.
10. Gupta N.A., Mells J., Dunham R.M., Grakoui A., Handy J., Saxena N.K., et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis invitro by modulating elements of the insulin signaling pathway. Hepatology 2010, 51(5):1584-1592.
11. Tushuizen M.E., Bunck M.C., Pouwels P.J., van Waesberghe J.H.T., Diamant M., Heine R.J. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver International: Official Journal of the International Association for the Study of the Liver 2006, 26(8):1015-1017.
12. Ding X., Saxena N., Lin S., Gupta N., Anania F. Obesity pathogenesis; exendin-4, a GLP-1 receptor agonist, reverses hepatic steatosis in ob/ob mice. Obesity, Fitness and Wellness Week 2006, 43(1):173-181.
13. Parlevliet E.T., Wang Y., Geerling J.J., Schröder-Van der Elst J.P., Picha K., O'Neil K., et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE3-leiden mice. PloS One 2012, 7(11):e49152.
14. Panjwani N., Mulvihill E.E., Longuet C., Yusta B., Campbell J.E., Brown T.J., et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013, 154(1):127.
15. Trevaskis J.L., Griffin P.S., Wittmer C., Neuschwander-Tetri B., Brunt E.M., Dolman C.S., et al. Glucagon-like peptide-1 (GLP-1) receptor agonism improves metabolic, biochemical and histopathological indices of nonalcoholic steatohepatitis (NASH) in mice. American Journal of Physiology. Gastrointestinal and Liver Physiology 2012, 302(8):G762-G772.
16. Flock G., Baggio L.L., Longuet C., Drucker D.J. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007, 56(12):3006-3013.
17. Dunphy J.L., Taylor R.G., Fuller P.J. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Molecular and Cellular Endocrinology 1998, 141(1-2):179-186.
18. Aviv V., Meivar-Levy I., Rachmut I.H., Rubinek T., Mor E., Ferber S. Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. Journal of Biological Chemistry 2009, 284(48):33509-33520.
19. Larsen P.J., Tang-Christensen M., Holst J.J., Ørskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997, 77(1):257-270.
20. Knauf C., Cani P.D., Perrin C., Iglesias M.A., Maury J.F., Bernard E., et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. Journal of Clinical Investigation 2005, 115(12):3554-3563.
21. Nogueiras R., Perez-Tilve D., Veyrat-Durebex C., Morgan D.A., Varela L., Haynes W.G., et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. Journal of Neuroscience 2009, 29(18):5916.
22. Taghibiglou C., Carpentier A., Van Iderstine S.C., Chen B., Rudy D., Aiton A., et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. Journal of Biological Chemistry 2000, 275(12):8416-8425.
23. Taghibiglou C., Rudy D., Van Iderstine S.C., Aiton A., Cavallo D., Cheung R., et al. Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes. Journal of Lipid Research 2000, 41(4):499.
24. Basciano H., Miller A.E., Naples M., Baker C., Kohen R., Xu E., et al. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. American Journal of Physiology. Endocrinology and Metabolism 2009, 297(2):E462-E473.
25. Yue J.T.Y., Mighiu P.I., Naples M., Adeli K., Lam T.K.T. Glycine normalizes hepatic triglyceride-rich VLDL secretion by triggering the CNS in high-fat fed rats. Circulation Research 2012, 110(10):1345-1354.
26. Lee J., Hong S., Chae S.W., Kim D.H., Choi J.H., Bae J.C., et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PloS One 2012, 7(2):e31394.
27. Williams D.L. Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology 2009, 150(7):2997-3001.
28. Yao Z., Tran K., McLeod R.S. Intracellular degradation of newly synthesized apolipoprotein B. Journal of Lipid Research 1997, 38(10):1937.
29. Sharma S., Mells J.E., Fu P.P., Saxena N.K., Anania F.A. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLOS One 2011, 6(9).
30. Kern M., Klöting N., Niessen H.G., Thomas L., Stiller D., Mark M., et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PloS One 2012, 7(6):e38744.
31. Minehira K., Vega N., Vidal H., Acheson K., Tappy L. Effect of carbohydrate overfeeding on whole body macronutrient metabolism and expression of lipogenic enzymes in adipose tissue of lean and overweight humans. International Journal of Obesity 2004, 28(10):1291-1298.
32. Svegliati-Baroni G., Saccomanno S., Rychlicki C., Agostinelli L., De Minicis S., Candelaresi C., et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced bya high-fat diet in nonalcoholic steatohepatitis. Liver International 2011, 31(9):1285-1297.
33. Richards P., Parker H.E., Adriaenssens A.E., Hodgson J.M., Cork S.C., Trapp S., et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014, 63(4):1224.
34. Bruinstroop E., Pei L., Ackermans M.T., Foppen E., Borgers A.J., Kwakkel J., et al. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes 2012, 61(5):1043.
35. Lam T.K.T., Gutierrez-Juarez R., Pocai A., Bhanot S., Tso P., Schwartz G.J., et al. Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. Nature medicine 2007, 13(2):171-180.
36. Cabou C., Campistron G., Marsollier N., Leloup C., Cruciani-Guglielmacci C., Pénicaud L., et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008, 57(10):2577-2587.
37. Vahl T.P., Tauchi M., Durler T.S., Elfers E.E., Fernandes T.M., Bitner R.D., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148(10):4965-4973.
38. Baggio L.L., Huang Q., Cao X., Drucker D.J. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008, 134(4):1137-1147.